Aminoglycoside-modifying enzymes determine the innate susceptibility to aminoglycoside antibiotics in rapidly growing mycobacteria

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 5, 2014, Pages 1412-1419

  Maurer, Florian P ^a,b   Bruderer, Vera L ^a   Castelberg, Claudio ^a   Ritter, Claudia ^a,b   Scherbakov, Dimitri ^a   Bloemberg, Guido V ^a   Böttger, Erik C ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Nationales Zentrum fur Mykobakterien   (Switzerland)

Author keywords

Amikacin; Cystic fibrosis; Drug resistance; Mycobacterium abscessus; Tobramycin

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOGLYCOSIDE MODIFYING ENZYME; BACTERIAL ENZYME; DIBEKACIN; KANAMYCIN A; KANAMYCIN B; TOBRAMYCIN; UNCLASSIFIED DRUG; ACYLTRANSFERASE; AMINOGLYCOSIDE; AMINOGLYCOSIDE ACETYLTRANSFERASE; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; COMPARATIVE STUDY; DISEASE PREDISPOSITION; DRUG ACETYLATION; DRUG SENSITIVITY; ENZYME ACTIVITY; GENETIC MANIPULATION; IC50; INVESTIGATIVE PROCEDURES; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM SMEGMATIS; NONHUMAN; RNA TRANSLATION; THIN LAYER CHROMATOGRAPHY; UPREGULATION; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; BIOTRANSFORMATION; DRUG EFFECTS; ENZYMOLOGY; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ACETYLTRANSFERASES; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BIOTRANSFORMATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA;

EID: 84929736533     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku550     Document Type: Article

References (48)

1. Griffith DE, Girard WM, Wallace RJ Jr. Clinical features of pulmonary disease caused by rapidly growingmycobacteria. An analysis of 154 patients. Am Rev Respir Dis 1993; 147: 1271-8.
2. Sermet-Gaudelus I, Le Bourgeois M, Pierre-Audigier C et al. Mycobacterium abscessus and children with cystic fibrosis. Emerg Infect Dis 2003; 9: 1587-91.
3. Esther CR Jr, Esserman DA, Gilligan P et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9: 117-23.
4. Maurer FP, Castelberg C, von Braun A et al. Postsurgical wound infections due to rapidly growing mycobacteria in Swiss medical tourists following cosmetic surgery in Latin America between 2012 and 2014. Euro Surveill 2014; 19: pii1/420905.
5. Bechara C, Macheras E, Heym B et al. Mycobacterium abscessus skin infection after tattooing: first case report and review of the literature. Dermatology 2010; 221: 1-4.
6. Nash KA, Brown-Elliott BA,Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53: 1367-76.
7. Bastian S, Veziris N, Roux AL et al. Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 2011; 55:775-81.
8. Kim HY, Kim BJ, Kook Y et al. Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol Immunol 2010; 54: 347-53.
9. Leao SC, Tortoli E, Euzeby JP et al. Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol 2011; 61: 2311-3.
10. Chopra S, Matsuyama K, Hutson C et al. Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae. J Antimicrob Chemother 2011; 66:1533-6.
11. Jarand J, Levin A, Zhang L et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011; 52: 565-71.
12. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement:diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
13. Magnet S, Blanchard JS. Molecular insights into aminoglycoside action and resistance. Chem Rev 2005; 105: 477-98.
14. Schatz A, Waksman SA. Effect of streptomycin and other antibiotic substances upon Mycobacterium tuberculosis and related organisms. Proc Soc Exp Biol Med 1944; 57: 244-8.
15. Levison ME. Pharmacodynamics of antimicrobial drugs. Infect Dis Clin N Am2004; 18: 451-65, vii.
16. Maurer FP, Bruderer VL, Ritter C et al. Lack of antimicrobial bactericidal activity in Mycobacterium abscessus. Antimicrob Agents Chemother 2014; 58: 3828-36.
17. Matt T, Ng CL, Lang K et al. Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin. Proc Natl Acad Sci USA 2012; 109: 10984-9.
18. Perez-Fernandez D, Shcherbakov D, Matt T et al. 4′-O-substitutions determine selectivity of aminoglycoside antibiotics. Nat Commun 2014; 5: 3112.
19. Duscha S, Boukari H, Shcherbakov D et al. Identification and evaluation of improved 4′-O-(alkyl) 4,5-disubstituted 2-deoxystreptamines as next generation aminoglycoside antibiotics. mBio 2014; 5: e01827-14.
20. Sander P, Prammananan T, Böttger EC. Introducing mutations into a chromosomal rRNA gene using a genetically modified eubacterial host with a single rRNA operon. Mol Microbiol 1996; 22: 841-8.
21. Prammananan T, Sander P, Brown BA et al. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J Infect Dis 1998; 177: 1573-81.
22. Hobbie SN, Pfister P, Brull C et al. Analysis of the contribution of individual substituents in 4,6-aminoglycoside-ribosome interaction. Antimicrob Agents Chemother 2005; 49: 5112-8.
23. Shcherbakov D, Akbergenov R, Matt T et al. Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in-vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol Microbiol 2010; 77: 830-40.
24. Böttger EC. Transmission of M. abscessus in patients with cystic fibrosis. Lancet 2013; 382: 503-4.
25. Galimand M, Courvalin P, Lambert T. Plasmid-mediated high-level resistance to aminoglycosides in Enterobacteriaceae due to 16S rRNA methylation. Antimicrob Agents Chemother 2003; 47: 2565-71.
26. Wachino J, Shibayama K, Kurokawa H et al. Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. Antimicrob Agents Chemother 2007; 51: 4401-9.
27. Shaw KJ, Rather PN, Hare RS et al. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycosidemodifying enzymes. Microbiol Rev 1993; 57: 138-63.
28. Swiatlo E, Kocka FE. Inducible expression of an aminoglycoside-acetylating enzyme in Providencia stuartii. J Antimicrob Chemother 1987; 19: 27-30.
29. Macinga DR, Rather PN. The chromosomal 2′-N-acetyltransferase of Providencia stuartii: physiological functions and genetic regulation. Front Biosci 1999; 4: D132-40.
30. Shaw KJ, Rather PN, Sabatelli FJ et al. Characterization of the chromosomal aac(6′)-Ic gene from Serratia marcescens. Antimicrob Agents Chemother 1992; 36: 1447-55.
31. Koskiniemi S, Pranting M, Gullberg E et al. Activation of cryptic aminoglycoside resistance in Salmonella enterica. Mol Microbiol 2011; 80:1464-78.
32. Zeng L, Jin S. aph(3′)-IIb, a gene encoding an aminoglycosidemodifying enzyme, is under the positive control of surrogate regulator HpaA. Antimicrob Agents Chemother 2003; 47: 3867-76.
33. Hull SI,Wallace RJ Jr, Bobey DG et al. Presence of aminoglycoside acetyltransferase and plasmids in Mycobacterium fortuitum. Lack of correlation with intrinsic aminoglycoside resistance.AmRev Respir Dis 1984; 129: 614-8.
34. Udou T, Mizuguchi Y, Wallace RJ Jr. Patterns and distribution of aminoglycoside-acetylating enzymes in rapidly growing mycobacteria. Am Rev Respir Dis 1987; 136: 338-43.
35. Ainsa JA, Martin C, Gicquel B et al. Characterization of the chromosomal aminoglycoside 2′-N-acetyltransferase gene from Mycobacterium fortuitum. Antimicrob Agents Chemother 1996; 40: 2350-5.
36. Pfister P, Hobbie S, Vicens Q et al. The molecular basis for A-site mutations conferring aminoglycoside resistance: relationship between ribosomal susceptibility and X-ray crystal structures. Chembiochem 2003; 4:1078-88.
37. Snapper SB, Melton RE, Mustafa S et al. Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis. Mol Microbiol 1990; 4: 1911-9.
38. Ainsa JA, Perez E, Pelicic V et al. Aminoglycoside 2′-N-acetyltransferase genes are universally present in mycobacteria: characterization of the aac(2′)-Ic gene from Mycobacterium tuberculosis and the aac(2′)-Id gene from Mycobacterium smegmatis. Mol Microbiol 1997; 24: 431-41.
39. Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes-Second Edition: Approved Standard M24-A2. CLSI, Wayne, PA, USA, 2011.
40. Medjahed H, Reyrat JM. Construction of Mycobacterium abscessus defined glycopeptidolipid mutants: comparison of genetic tools. Appl Environ Microbiol 2009; 75: 1331-8.
41. Pawlik A, Garnier G, Orgeur M et al. Identification and characterization of the genetic changes responsible for the characteristic smooth-to-rough morphotype alterations of clinically persistent Mycobacterium abscessus. Mol Microbiol 2013; 90: 612-29.
42. Ripoll F, Pasek S, Schenowitz C et al. Nonmycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PLoS One 2009; 4: e5660.
43. Morris RP, Nguyen L, Gatfield J et al. Ancestral antibiotic resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2005; 102: 12200-5.
44. Geiman DE, Raghunand TR, Agarwal N et al. Differential gene expression in response to exposure to antimycobacterial agents and other stress conditions among seven Mycobacterium tuberculosis whiB-like genes. Antimicrob Agents Chemother 2006; 50: 2836-41.
45. Ainsa JA, Blokpoel MC, Otal I et al. Molecular cloning and characterization of Tap, a putativemultidrug efflux pump present in Mycobacteriumfortuitum and Mycobacterium tuberculosis. J Bacteriol 1998; 180: 5836-43.
46. Ramon-Garcia S, Mick V, Dainese E et al. Functional and genetic characterization of the tap efflux pump in Mycobacterium bovis BCG. Antimicrob Agents Chemother 2012; 56: 2074-83.
47. Buriankova K, Doucet-Populaire F, Dorson O et al. Molecular basis of intrinsic macrolide resistance in the Mycobacterium tuberculosis complex. Antimicrob Agents Chemother 2004; 48: 143-50.
48. Boehm A, Steiner S, Zaehringer F et al. Second messenger signalling governs Escherichia coli biofilm induction upon ribosomal stress. Mol Microbiol 2009; 72: 1500-16.